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Background: A plethora of studies have shown elevated preoperative natriuretic peptide measurements to predict postopera-
tive mortality and adverse cardiac events.
Objectives: The current study aimed to demonstrate this overwhelming association and to show that further studies of this 
nature are unwarranted.
Methods: A cumulative meta-analysis of 28 studies was conducted where the primary outcomes of mortality and adverse cardiac 
events were associated with elevated preoperative natriuretic peptides.
Results: Cumulative meta-analysis demonstrated an odds ratio trending to a constant of 5.66, with a marked narrowing in the 
95% confidence interval.
Conclusions: Further studies aiming only to demonstrate an association between a preoperative natriuretic peptide threshold 
and the risk of postoperative adverse cardiac events are not justified. Future investigation should focus on the clinical impli-
cations of these data and the application of these findings with regard to further investigation, optimisation and appropriate 
adaptation of perioperative management.
Keywords: BNP, major adverse cardiac event, myocardial injury, natriuretic peptides, non-cardiac surgery, NT-proBNP, outcomes
Introduction
The prediction of postoperative mortality and adverse cardiac 
events remains challenging, and clinical risk models and cardiac 
stress testing (e.g. cardiopulmonary, radioisotope and 
dobutamine stress testing) have met with limited success. 
However, over the last 10 years,1 multiple studies have examined 
the ability of preoperative B-type natriuretic peptides (NP) (i.e. 
B-type natriuretic peptide [BNP] or N-terminal fragment of 
proBNP [NT-proBNP]), which are released from cardiac myocytes 
and fibroblasts in response to myocardial stretch, ischaemia and 
other neuro-endocrine stimuli,2,3 to predict these events.
Almost uniformly every study conducted in non-cardiac surgical 
populations has reported that preoperative NP measurement 
elevations are predictive of short (≤ 30 day), intermediate (>30–
180 day) and long-term (>180 day) postoperative mortality,4 as 
well as major adverse cardiac events such as myocardial 
infarction, troponin elevation, cardiac failure, and atrial 
fibrillation. This signal has been repeatedly demonstrated in 
multiple meta-analyses.5–8
In the face of this consistent and overwhelming signal we believe 
the point has been reached where current data clearly 
demonstrate that elevated preoperative NP measurements are 
undoubtedly associated with postoperative mortality and major 
adverse cardiac events.
To test this hypothesis and in accordance with the Preferred 
Reporting Items for Reviews and Meta-Analyses (PRISMA) 
statement, we conducted a cumulative meta-analysis with the 
aim to address the question: Is the cumulative evidence for the 
ability of NPs to predict major adverse cardiac outcomes at 
30  days after non-cardiac surgery sufficiently strong such that 
further studies designed to examine similar outcomes are 
unwarranted?
A cumulative meta-analysis can be considered a series of meta-
analyses, with each subsequent analysis in the sequence 
including all previous studies as well as any additional studies.9 
The chronological combination of studies can track the 
progression of evidence over time; demonstrate consistency in 
results of prior and subsequent studies; and can potentially 
identify a point where, due to multiple studies showing the same 
outcomes, no further studies are necessary.10
Methods
We conducted a cumulative meta-analysis, including studies 
where the primary outcome was a composite of mortality and 
adverse cardiac outcomes. Adverse cardiac outcomes included: 
non-fatal myocardial infarction (MI), myocardial injury after non-
cardiac surgery (MINS), electrocardiogram (ECG) evidence of 
ischaemia (new Q-waves or ST segment changes), evidence of 
new onset or decompensated congestive cardiac failure, new 
onset or haemodynamically unstable arrhythmias (atrial 
fibrillation/flutter or ventricular tachyarrhythmias), and the need 
for percutaneous coronary intervention (PCI). The protocol for 
this study was not published.
Databases and search strategy
In October 2014, we searched the following online databases, 
using the OvidSP search engine (Ovid Technologies, Inc., New 
York, NY, 2009): EMBASE 1980 to 2012, Week 28; OVID Health Star 
(1966 to June 2013); OVID MEDLINE(R) In-Process & Other Non-
Indexed Citations and AVID MEDLINE(R) 1946 to present: 
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Cochrane Central Register of Controlled Trials (June 2012); 
Cochrane Database of Systematic Reviews (June 2012) and 
ProQuest Dissertations and Theses A&I (June 2012). The search 
terms and an example of the search methodology used are listed 
in Appendix 1. No language filters were used.
Study selection and inclusion
We included all observational studies or randomised controlled 
trials (RCTs) reporting on adult patients undergoing non-cardiac 
surgery, where NPs were measured preoperatively (up to one 
month prior to surgery), and where the authors reported all-
cause mortality or a major adverse cardiac outcome up to 
30  days after surgery. Studies were included regardless of 
language, sample size and publication status. We excluded 
studies examining cardiac surgery, paediatric studies, and those 
where NPs were measured postoperatively only.
Eligibility assessment
The titles and abstracts of each citation found in the search were 
independently screened by two people (DS, DP). These screeners 
noted citations they felt had a possibility of meeting the criteria 
for eligibility to undergo further review. If either reviewer felt the 
citation might contain a relevant study, the article was retrieved 
to undergo full text evaluation. Full texts of all citations identified 
as being potentially relevant were then independently evaluated 
by both DS and DP to determine eligibility. Disagreements were 
adjudicated by a third person (RR). Chance-corrected inter-
observer agreement for study eligibility was tested using kappa 
statistics.
Data extraction
Data were extracted from the eligible studies by CR and LR and 
disagreements resolved by consensus. Descriptive data 
abstracted from all eligible studies included: year of publication, 
study design, sample size, patient population, type of surgery, 
type of NP assay used (i.e. BNP or NT-proBNP), critical NP 
threshold, study outcomes, and the number of events recorded. 
Where required, authors were contacted to confirm abstracted 
data, to provide missing data, and for viewing of their complete 
data sets.
From each study we extracted the adjusted odds ratio (OR) and 
95% confidence interval (CI) associated with a preoperative NP 
measurement above the study-specific NP threshold for the 
primary composite outcome of postoperative all-cause mortality 
and/or adverse cardiac outcomes. In studies where the OR was 
not reported, we converted the hazard ratio (HR) or relative risk 
(RR) to odds ratio using the following formulae, where OR = odds 
ratio, RR = relative risk, HR = hazard ratio:
or extracted the OR from a previously published meta-analysis 
that made use of original study data to determine adjusted ORs.6 
RR commonly underestimates the OR, therefore where RR could 
not be converted to OR, RR was used in the analysis. We then 
performed a separate cumulative meta-analysis, including only 
the studies where only OR was reported.
Adverse cardiac outcomes included non-fatal myocardial 
infarction (MI), myocardial injury after non-cardiac surgery 















ischaemia (new Q-waves or ST segment changes), evidence of 
new onset or decompensated congestive cardiac failure, new 
onset or haemodynamically unstable arrhythmias (atrial 
fibrillation/flutter or ventricular tachyarrhythmias), or the need 
for percutaneous coronary intervention (PCI). Cumulative meta-
analysis was conducted using Comprehensive Meta Analysis 




The database search using the search terms described above 
yielded 1 292 study citations. The initial screening process 
excluded 1 174 unsuitable studies, leaving 118 studies for full 
text evaluation. After full text evaluation 22 citations were 
excluded as they yielded abstracts only and nine citations were 
excluded because they had been retracted due to fraud. Another 
34 studies were excluded for the following reasons: cardiac 
surgery (2); no study end-points collected (5); no surgery 
conducted (4); editorial or letter to the editor (3); postoperative 
NP measured (3); no preoperative NP measurement (4); meta-
analysis (7), review article (1). Five studies were excluded as they 
did not examine the required outcome. Inter-observer agreement 
for study eligibility was good (kappa = 0.7).
The remaining 53 studies were then assessed to determine their 
suitability for inclusion in the meta-analysis. At this point, 14 
studies were excluded as they reported no adjusted OR,11–24 3 
studies were excluded because 30-day outcomes were not 
provided,25–27 and 6 studies were excluded as they were 
duplications of previously included/excluded studies.21,27–31 One 
study32 was excluded because the patient cohort was part of the 
full cohort presented in another included paper, and one was 
excluded because multiple BNP thresholds were used.33 Figure 1 
summarises the studies that were excluded from the analysis, 
and the reasons therefor. After the above exclusions we were 
able to include 28 studies29,34–60 in the cumulative meta-analysis.
Figure 1: Study selection process.
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Study characteristics
Table 1 describes the characteristics of the studies included in 
this cumulative meta-analysis. The average age of the patients 
ranged from 57 to 87 years. In 24 of the 28 included publications 
(85.7%), the patients were undergoing elective surgery. Of the 
remaining studies, three reported exclusively on patients 
undergoing emergency surgery,38,45,48 and one documented 
both elective and emergency surgeries that were classified as 
being high risk.46
Certain studies investigated outcomes in a specific surgical 
discipline, including thoracic surgery (4),36,50,51,54 vascular 
(7),29,40,42,44,55,57,59 orthopaedic (5),45,47–49,60 major abdominal (1),56 
oesophagectomy (1),41 while the rest documented outcomes 
following a variety of surgeries performed (10),34,35,37–39,43,46,52,53,58 
including a mix of general, head and neck, gynaecological, 
orthopaedic, vascular, urological, neurosurgery and thoracic 
surgery.
The study outcomes included all-cause mortality, cardiac death, 
non-fatal myocardial infarction (MI), myocardial injury after non-
cardiac surgery (MINS) as evidenced by troponin elevation, ECG 
evidence of ischaemia (new Q-waves or ST segment changes), 
evidence of new onset or decompensated congestive cardiac 
failure, new onset or haemodynamically unstable arrhythmias 
(atrial fibrillation/flutter or ventricular tachyarrhythmias) or the 
need for percutaneous coronary intervention).
Primary outcome definitions, myocardial infarction criteria and 
cardiac troponin levels used to define myocardial injury for each 
study are summarised in Appendix 2.
Preoperative NP measurements
Table 2 summarises the details of the NP measured and the 
assays used to determine the NP levels in the included studies, 
the manufacturers thereof, as well as the discriminatory 
thresholds employed by the authors when reporting the ORs for 
the respective studies.
Study quality
We performed an analysis of the quality of the studies included 
in the cumulative meta-analysis. These findings are summarised 
in Table 3.
Study design
In total, 24 of the 28 studies29,34–38,40–43,46–53,55–60 were prospective 
observational cohort studies. Of the remaining four studies: 
Table 1: Study characteristics of eligible studies
Author, year Surgery type Patients Events Outcome definitions
Yeh, 2005 Elective non-cardiac 190 15 MACE
Dernellis, 2006 Elective non-cardiac 1590 96 MACE
Cardinale, 2007 Elective thoracic 400 72 AF
Cuthbertson, 2007 Elective major non-cardiac 204 12 MACE
Cuthbertson, 2007 Emergency hip and abdominal 40 11 MACE
Gibson, 2007 Elective major non-cardiac 190 26 MACE
Mahla, 2007 Elective vascular 218 44 MACE, acute coronary revascularisation
Hou, 2007 Elective oesophagectomy 142 11 MACE
Rajagopalan, 2008 Elective major vascular 136 28 Myocardial injury
Yun, 2008 Elective non-cardiac 279 25 MACE, non-fatal stroke
Bolliger, 2009 Elective major vascular 133 19 MACE
Oscarsson, 2009 Emergency hip 69 34 MACE
Schutt, 2009 Elective & emergency non-cardiac 25 83 Heart failure, unstable angina
Breidthardt, 2010 Elective orthopaedic 270 4 MACE, troponin elevation, ECG changes
Chong, 2010 Emergency orthopaedic 89 65 MACE
Villacorta, 2010 Elective orthopaedic 208 17 MACE
Lee, 2011 Elective thoracic 98 10 MACE, ECG changes
Nojiri, 2011 Elective thoracic 80 34 Cardiorespiratory complications
Park, 2011 Elective major non-cardiac 1923 355 MACE
Payne, 2011 Elective non-cardiac 345 111 Long term all-cause mortality
Amar, 2012 Elective thoracic 415 65 AF
Biccard, 2012 Elective vascular 788 136 Mortality, troponin elevation
Mercantini, 2012 Elective major abdominal 205 31 MACE, troponin elevation
Yang, 2012 Elective vascular 365 63 MACE
Bryce, 2013 Elective abdominal aortic aneurysm 106 29 MACE, all-cause mortality
Borges, 2013 Elective non-cardiac 145 17 Vascular death, non-fatal MI, non-fatal cardiac arrest
Scrutinio, 2014 Elective vascular 411 87 Death, ACS, acute pulmonary oedema, postoperative myocardial damage
Vetrugno, 2014 Elective orthopaedic 227 14 MACE
Notes: AF: atrial fibrillation; MACE: major adverse cardiac events (cardiac death, non-fatal myocardial infarction, congestive cardiac failure, arrhythmias); ACS: acute coronary 
syndrome; ECG: electrocardiograph.
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Troponin screening
Routine postoperative troponin screening was documented in 
17 of the 28 papers (60.7%) included in the analysis. In the studies 
where troponin screening was not routine, four studies34,35,47,49 
indicated that troponin testing was guided by clinical signs or at 
the discretion of the attending doctors. The specific systems and 
assays used to measure troponin levels are shown in Table 3.
Association between NPs and postoperative major 
adverse cardiac events and mortality
All associations between elevated NP levels and major adverse 
cardiac events were calculated using multivariate logistic 
regression analysis. The 28 eligible studies incorporated a total of 
9291 patients, among which there were 1514 documented 
adverse cardiac events. All of the included studies demonstrated 
that an elevated preoperative NP measurement was an 
independent predictor of the primary study outcome.
Figure 2 presents t he results of the cumulative meta-analysis of 
the 28 studies reporting an adjusted OR for the composite of all-
cause mortality or adverse cardiac outcomes in patients with an 
elevated preoperative NP measurement. These results show that, 
with cumulative data over time (from 2005 to 2014), the 
one39 was a prospective derivation study with a subsequent 
validation study performed; one44 was a prospective pre-
specified secondary analysis of a cohort in a placebo-controlled 
randomised controlled trial (RCT); one45 was a cohort extracted 
from a prospective observational study; and one54 was a 
retrospective review of patients enrolled in a different study with 
prospectively collected data.
Blinding
In 13 of the 28 studies (46.4%), it was indicated that both data 
collection and outcome assessment were performed by 
investigators blinded to the NP value. Four of the studies35,45,47,54 
specifically reported that the investigators performing data 
collection and outcome assessment were not blinded, while in 
10 of the studies blinding was not indicated. In one study53 the 
investigators collecting the data were blinded to the NP value, 
while those performing outcome assessment were not.
Outcome definitions
Consistent outcome definitions were utilised in all 28 included 
papers.
Figure 2: Cumulative risk for postoperative mortality or major adverse cardiac events associated with an elevated preoperative BNP or NT-proBNP 
measurement.
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trend towards a constant (± 5.66), with the 95% confidence 
intervals growing progressively smaller with the addition of 
subsequent studies, an indication that the cumulative OR is 
increasingly likely to represent the ‘true’ association. Indeed, we 
believe the data now overwhelmingly demonstrate this 
association, and further small studies that aim to demonstrate a 
similar association are unwarranted.
Rather, future studies in this field should be directed at using this 
information to improve patient outcome. Large studies 
conducted across multiple surgical populations, which make use 
of robust statistical methods, are required to identify clinically 
relevant NP risk thresholds able to change clinical decision-
making. This research should focus on a number of important 
questions. First, is there an NP level that warrants delaying 
elective surgery in order to investigate and optimise coexisting 
medical conditions? This may include initiation of ‘best medical 
therapy’ or percutaneous coronary intervention (PCI). Second, 
can we demonstrate the reliability of NP changes to monitor 
response to PCI or medical therapy in the absence of cardiac 
failure? Third, is there benefit in adjusting anaesthetic or surgical 
technique and level of perioperative care in patients with 
elevated NP levels? What would the cost implications of this be 
and would it improve outcome? Lastly, is there an NP level at 
which it might be advisable to avoid surgery altogether due to 
an unacceptably high probability of cardiac morbidity or 
incorporation of each subsequent study into the cumulative 
analysis shifts the cumulative OR progressively towards a 
constant number. The cumulative ORs appearing in the lower 
third of the forest plot demonstrate an almost vertical trend 
towards an OR of approximately 5.66. Second, whereas the 95% 
confidence interval at the start of the cumulative meta-analysis is 
wide, it becomes progressively narrower as additional studies 
are incorporated.
We conducted a sensitivity analysis that excluded the three 
studies where the OR was not primarily reported (one study53 
reported a HR, and two reported RR51,52). This analysis yielded 
similar results, producing a higher cumulative OR of 6.57. This is 
consistent with the tendency for RR to underestimate OR and the 
actual association, so the inclusion of these three studies in the 
cumulative meta-analysis probably produces a conservative 
estimation of the true association.
Discussion
This cumulative meta-analysis confirms that the measurement of 
an elevated BNP or NT-proBNP is clearly and undoubtedly 
associated with an increased risk of death and major adverse 
cardiac outcomes. Importantly, this demonstrates that with each 
subsequent study added into the sequential analysis, the signal 
becomes progressively clearer and increasingly well defined. The 
cumulative odds ratio (OR) for the combined studies is seen to 
Table 2: Natriuretic peptide assay characteristics
Author, year Natriuretic peptide measured Assay, Manufacturer Threshold (pg/ml)
Yeh, 2005 NT-proBNP Elecsys, Roche diagnostics 450
Dernellis, 2006 BNP AxSYM, Axis Shield diagnostics 189
Cardinale, 2007 NT-proBNP Elecsys, Roche diagnostics 204
Cuthbertson, 2007 BNP Bayer ADVIA Centaur, Siemens medical diagnostics 40
Cuthbertson, 2007 BNP Bayer ADVIA Centaur, Siemens medical diagnostics 170
Gibson, 2007 BNP Not indicated 108.5
Mahla, 2007 NT-proBNP Elecsys, Roche diagnostics 280
Hou, 2007 NT-proBNP Elecsys, Roche diagnostics Not indicated
Rajagopalan, 2008 NT-proBNP Elecsys, Roche diagnostics 308
Yun, 2008 NT-proBNP Elecsys, Roche diagnostics 201
Bolliger, 2009 BNP AxSYM, Axis Shield diagnostics 50
Oscarsson, 2009 NT-proBNP Stratus CS Acute Care Diagnostic System 3984
Schutt, 2009 NT-proBNP Elecsys, Roche diagnostics 457
Breidthardt, 2010 BNP Fluorescence immunoassay, Biosite diagnostics 174
Chong, 2010 NT-proBNP Elecsys, Roche diagnostics 842
Villacorta, 2010 BNP Triage, Biosite Inc 60
Lee, 2011 NT-proBNP Elecsys, Roche diagnostics 160
Nojiri, 2011 BNP Shionogi BNP, Shionogi Pharmaceuticals 30
Park, 2011 NT-proBNP Elecsys, Roche diagnostics 301
Payne, 2011 BNP Shionoria BNP Kit (Shinogi & Co) 87.5
Amar, 2012 BNP Not indicated 30
Biccard, 2012 BNP Bayer ADVIA Centaur, Siemens medical diagnostics 48.1
Mercantini, 2012 BNP Triage, Biosite Inc 36
Yang, 2012 NT-proBNP Not indicated 302
Bryce, 2013 BNP Shinoria BNP Kit, Shinogi & Co Ltd 99.5
Borges, 2013 NT-proBNP Elecsys, Roche diagnostics 917
Scrutinio, 2014 NT-proBNP Not indicated Not indicated
Vetrugno, 2014 BNP Bayer ADVIA Centaur, Siemens medical diagnostics 39
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Table 3: Study quality characteristics
Author, year Study design Data collection 
















Yeh, 2005 Prospective obser-
vational cohort
Blinded Blinded Yes No, troponin testing 
guided by clinical 
signs
Not specified
Dernellis, 2006 Prospective obser-
vational cohort
Not blinded Not blinded Yes No, troponin testing 
guided by clinical 
signs
Not specified
Cardinale, 2007 Prospective obser-
vational cohort
Blinded Blinded Yes No Not applicable
Cuthbertson, 2007 Prospective obser-
vational cohort
Blinded Blinded Yes Yes 2nd generation, Bayer 
ADVIA Centaur, Tro-
ponin I > 0.32 ng/ml
Cuthbertson, 2007 Prospective obser-
vational cohort
Blinded Blinded Yes Yes 2nd generation, Bayer 
ADVIA Centaur, Tro-
ponin I> 0.1 ng/ml




Blinded Blinded Yes Yes 2nd generation, Bayer 
ADVIA Centaur, no 
threshold indicated
Mahla, 2007 Prospective obser-
vational cohort
Blinded Blinded Yes Yes 4th generation, Roche 
Elecsys Troponin T 
STAT, > 0.03 ng/ml)
Hou, 2007 Prospective obser-
vational cohort
Not indicated Not indicated Yes No Not applicable
Rajagopalan, 2008 Prospective obser-
vational cohort
Not indicated Not indicated Yes Yes 2nd generation Bayer 
ADVIA Centaur, Tro-
ponin I > 0.1 ng/ml
Yun, 2008 Prospective obser-
vational cohort
Not indicated Not indicated Yes Yes Troponin T, assay not 
specified, no thresh-
old indicated
Bolliger, 2009 Prospective pre-
specified secondary 
analysis of cohort 
in a placebo-con-
trolled RCT
Blinded Blinded Yes Yes 1st generation Abbott 
AxSYM Troponin I, > 
2 ng/ml
Oscarsson, 2009 Cohort extracted 
from prospective 
observational study
Not blinded Not blinded Yes Yes High sensitivity, 
Siemens Stratus CS 
acute care Troponin I, 
> 0.06 ng/ml
Schutt, 2009 Prospective obser-
vational cohort
Blinded Blinded Yes No Not specified
Breidthardt, 2010 Prospective obser-
vational cohort
Not blinded Not blinded Yes No, troponin testing 
at discretion of 
treating physician
1st generation Abbott 
AxSYM Troponin I, > 
2 ng/ml
Chong, 2010 Prospective obser-
vational cohort
Blinded Blinded Yes Yes 4th generation 
Abbott Architect STAT 
Troponin I, > 0.03 ng/
ml
Villacorta, 2010 Prospective obser-
vational cohort
Not indicated Not indicated Yes No, troponin testing 
guided by clinical 
signs
Not specified
Lee, 2011 Prospective obser-
vational cohort
Not indicated Not indicated Yes No Not specified
Nojiri, 2011 Prospective obser-
vational cohort
Not indicated Not indicated Yes No Not specified
Park, 2011 Prospective obser-
vational cohort
Not indicated Not indicated Yes Yes Troponin I (0.78 ng/
ml),assay not spec-
ified
Payne, 2011 Prospective obser-
vational cohort
Blinded Not blinded Yes Yes Troponin I, assay not 
specified
(Continued)
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inclusion would further narrow the associated 95% CI, thereby 
affirming our conclusions.
Conclusions
These results suggest that further small studies conducted solely 
to demonstrate an association between a study-specific 
preoperative NP threshold and the risk of postoperative mortality 
or adverse cardiac events are no longer justified. Future 
investigation should be focused on developing robust clinically 
applicable BNP or NT-proBNP thresholds from large 
representative perioperative populations that are adjusted for 
important preoperative risk factors. Attention should further be 
given to developing trials that demonstrate: that preoperative 
NP measurement is able to reduce postoperative mortality and 
adverse cardiovascular events; the cost effectiveness of NP 
measurement; and to determine if treating patients with 
elevated NP before surgery is able to improve patient outcomes.
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mortality? Should patients and families be given risk-algorithm 
models to empower them to assist with the decision-making 
process? These questions can only be answered once 
investigators move away from repeatedly demonstrating the 
already clear association between NP elevations and morbidity, 
and rather focus subsequent studies on using this information in 
order to change outcomes in the at-risk population.
Limitations
In some of the included studies, the NP thresholds were 
predetermined in the methodology of the study; however, the 
majority used the area under the receiver operator characteristic 
(ROC) curve to determine the NP level that best predicted the 
primary study outcome. Thus, the NP thresholds used varied 
markedly both for BNP (30–189 pg/ml) and for NT-proBNP (160–
3984 pg/ml).
Our decision to make use of varying definitions of adverse 
cardiac outcomes allowed us to compare our results with a 
previous seminal BNP/NT-proBNP meta-analysis by Karthikeyan 
et al., who made use of similar varying composite outcomes.6 
Further, despite these different outcome definitions we were 
able to demonstrate that the signal approaches a consistent 
odds ratio, which we believe adds further support to our findings.
Ten studies were excluded as they did not report adjusted ORs 
associated with elevated NP measurements; however, all of these 
studies reported a positive association with an elevated 
preoperative MP measurement and adverse cardiovascular 
outcomes. Therefore, while the addition of these studies would 
marginally change the point estimate of our analysis, their 
Author, year Study design Data collection 
















Amar, 2012 Retrospective 
review of patients 
enrolled in a differ-
ent study
Not blinded Not blinded Yes No Not applicable
Biccard, 2012 Prospective obser-
vational cohort
Not blinded Not blinded Yes Yes 2nd generation Sie-
mens Advia Centaur 
XP, Troponin > URL
Mercantini, 2012 Prospective obser-
vational cohort
Blinded Blinded Yes Yes 4th generation Tro-
ponin T(≥ 0.06 ng/ml)
Yang, 2012 Prospective obser-
vational cohort
Not indicated Not indicated Yes Yes Troponin I (0.78 ng/
ml),Roche Diag-
nostics, assay not 
specified
Bryce, 2013 Prospective mul-
ti-centre observa-
tional cohort
Blinded Blinded Yes Yes 4th generation 
Abbott Architect STAT 
Troponin I, no thresh-
old specified
Borges, 2013 Prospective obser-
vational cohort
Blinded Blinded Yes Yes 2nd generation 
Siemens cTnI Ultra, 
Troponin I > 0.04 ng/
ml
Scrutinio, 2014 Prospective obser-
vational cohort
Not indicated Not indicated Yes Yes 2nd generation 
Siemens RxL immuno-
assay, Troponin I > 
0.14 ng/ml
Vetrugno, 2014 Prospective obser-
vational cohort
Blinded Blinded Yes No Not specified
Table 3: (Continued)
Note: NP = B-type natriuretic peptides.
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Appendix 1
Search strategy and databases used
Search terms Number 
1 (Natriuretic peptide OR natriureti*).mp. 90 064
2 (BNP OR B type natriureti* OR B-type natriureti* OR Brain natriureti*).mp. 42 364
3 (NT-pro BNP OR NT-proBNP OR NT-pro-BNP OR N terminal proBNP OR N terminal pro-BNP OR N-terminal proBNP 
N terminal pro-BNP OR N-terminal pro-brain natriureti* OR N-terminal pro-B-type natriureti*OR N-terminal pro-B 
type natriureti*).mp
13 484
4 (Surgery OR operative OR non-cardiac).mp. 3 308 271
5 1 or 2 or 3 94 975
6 4 and 5 4 456
7 prognosis.sh. or diagnosed.tw. or cohort:.mp. or predictor:.tw. or death.tw. or exp models, statistical/ 4 837 473
8 6 and 7 1 433
9 remove duplicates from 8 876
Notes: No additional search filters were used.
For the EMBASE search the EMTree term ‘Brain natriuretic peptide’ was used.
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Appendix 2
Details of outcome definitions, criteria and thresholds used
Author, year Primary outcome definitions Myocardial infarction criteria Myocardial injury/damage/
necrosis criteria
Yeh, 2005 Cardiac death, ACS including MI and 
unstable angina, congestive cardiac 
failure and serious cardiac arrhythmia
Increased cardiac enzymes (creatine kinase MB 
isoenzyme or troponin I) and ECG evidence of 
myocardial infarction (new Q waves or ST-T wave 
changes) in at least two adjacent leads
N/A
Dernellis, 2006 Cardiac death, non-fatal MI, acute 
pulmonary oedema, ventricular 
arrhythmia
Cardiac enzyme increase greater than twice the 
upper limit of normal OR new Q wave on postop-
erative ECG plus cardiac enzyme rise consistent 
with necrosis
N/A
Cardinale, 2007 Atrial fibrillation N/A N/A
Cuthbertson, 2007 Death or myocardial injury N/A cTnI > 0.32 ng/ml
Cuthbertson, 2007 Cardiac death and/or new postoper-
ative myocardial injury and/or signifi-
cant postoperative ECG changes
N/A cTnI > 0.1 ng/ml
Gibson, 2007 Non-fatal MI and cardiac death Typical rise and fall of cTnI plus one of:  ischaemic 
symptoms, ECG changes (new Q waves or ST 
segment changes), or coronary intervention (ESC/
ACC definition)
N/A
Mahla, 2007 Non-fatal MI, acute coronary revascu-
larisation, cardiac death
Elevated cTnT and clinical or ECG changes indica-
tive of ischaemia
N/A
Hou, 2007 Atrial fibrillation N/A N/A
Rajagopalan, 2008 Myocardial injury N/A Elevated cTnI > 0.1 ng/ml
Yun, 2008 Cardiac death, ischaemic heart 
disease, acute pulmonary oedema or 
nonfatal stroke
Not specified Not specified
Bolliger, 2009 Any hospitalisation for myocardial 
revascularisation, acute coronary syn-
drome, acute congestive heart failure, 
or death by any cause
N/A N/A
Oscarsson, 2009 Myocardial damage, acute MI, and/
or death
Not specified cTnI > 0.06 ng/ml
Schutt, 2009 Postoperative MI heart failure, unsta-
ble angina, dysrhythmia, cardiac arrest
2 out of 3 of: symptoms consistent with myocar-
dial infarction, elevated troponin T level, or new 
diagnostic changes on electrocardiogram
N/A
Breidthardt, 2010 ECG changes, significant arrhythmias, 
myocardial necrosis, cardiac failure
N/A cTnI > 2 ng/ml 
Chong, 2010 Acute MI, congestive cardiac failure, 
atrial fibrillation, major arrhythmia
Standard definition 1 cTn I > 0.03 ng/ml
Villacorta, 2010 Acute MI, unstable angina, acute pul-
monary oedema, heart failure, acute 
atrial fibrillation, sustained ventricular 
tachycardia, cardiac death
Elevation of biomarkers more than 2 x upper limit 
of normal plus ECG changes
N/A
Lee, 2011 Myocardial injury, ECG evidence of 
ischaemia or arrhythmia, heart failure
N/A cTn T > 0.1 ng/ml
Nojiri, 2011 Arrhythmias, angina pectoris, MI, 
congestive cardiac failure, throm-
bo-embolic events
Not specified Not specified
Park, 2011 MI, pulmonary oedema, cardiovascular 
death
cTnI > 0.78 ng/ml (99th centile of upper reference 
limit)
N/A
Payne, 2011 Perioperatve death & MACE, long-term 
all-cause mortality
Not specified Not specified
Amar, 2012 Atrial fibrillation   N/A N/A
Biccard, 2012 Mortality, troponin elevation Not specified cTn > URL
Mercantini, 2012 Angina pectoris, STEMI, NSTEMI, tro-
ponin elevation, cardiac failure, acute 
hypertensive event
ST changes in two or more contiguous leads cTnI > 0.06 ng/ml,  cTnT > 0 ng/ml
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Author, year Primary outcome definitions Myocardial infarction criteria Myocardial injury/damage/
necrosis criteria
Bryce, 2013 Non-fatal MI, cardiac death, all-cause 
mortality
Troponin elevation and gradual decline plus one 
of: ischaemic symptoms, ECG changes (new Q 
waves or ST changes), or coronary artery inter-
vention
N/A
Borges, 2013 Vascular death, non-fatal MI, non-fatal 
cardiac arrest
Typical rise and fall of cTnI to > 0.04 ng/ml, plus 
one of: ischaemic symptoms, ECG changes (new 
Q wave, ST changes in two or more contiguous 
leads, or new LBBB)
N/A
Scrutinio, 2014 Death, ACS, acute pulmonary oedema, 
postoperative myocardial damage
Standard definition1 cTnI > 0.14 ng/ml
Vetrugno, 2014 New onset atrial fibrillation/flutter, 
acute heart failure or non-fatal/fatal MI
cTnI > 0.12 ng/ml (3 x upper reference limit) N/A
Appendix 2: (Continued)
